Drug intelligence / Profile preview

Cele-Pro

Development stage: Preclinical
Lead developer: Seaport Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Cele-Pro (also known as GlyphCele) is an oral prodrug of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, developed by Seaport Therapeutics in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS). The drug utilizes the proprietary Glyph™ platform, which is designed to facilitate drug absorption through the lymphatic system rather than the hepatic portal vein. By bypassing first-pass metabolism and targeting the gut lymphatics directly, Cele-Pro aims to restore gut lymphatic function. It is currently being investigated for the treatment of metabolic diseases and pancreatic cancer, supported by non-dilutive funding from the Advanced Research Projects Agency for Health (ARPA-H).

Other names: GlyphCele

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Cele-Pro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cele-Pro.

Explore the full profile